IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(4 sites)

United States

HonorHealth Cancer Center, Scottsdale, Arizona

Yale Cancer Center, New Haven, Connecticut

Memorial Sloan Kettering Cancer Center, New York, New York

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania